<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088083</url>
  </required_header>
  <id_info>
    <org_study_id>V1.0</org_study_id>
    <nct_id>NCT05088083</nct_id>
  </id_info>
  <brief_title>Paclitaxel-Coated Balloon for the Treatment of AVF</brief_title>
  <acronym>AVF</acronym>
  <official_title>Single-arm Study of Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon for the Treatment of Obstructive Lesions in the Native Arteriovenous Dialysis Fistulae (AVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Zylox Medical Device Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Zylox Medical Device Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the Zylox Drug Coated Balloon (DCB) for treatment of&#xD;
      subjects presenting with de novo or non-stented restenotic obstructive lesion of native&#xD;
      arteriovenous dialysis fistulae (AVF) in the upper extremity in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary patency of target lesion in 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Primary Patency is defined as the freedom of reintervention for the target lesion,including: 1)clinical driven target lesion reintervention; 2) PSVR&lt; 2.4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Time of procedure</time_frame>
    <description>Successful delivery to the target lesion, deployment, and retrieval at index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>From the time of the index procedure to the first successful dialysis session after index procedure. Typically, this is within 1 week of index procedure.</time_frame>
    <description>The resumption of dialysis for at least one session after the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>2 weeks</time_frame>
    <description>Maintenance of patency (≤30% residual stenosis) in the absence of peri-procedural serious adverse device effect (SADE).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">143</enrollment>
  <condition>Arteriovenous Fistula</condition>
  <arm_group>
    <arm_group_label>DCB Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with DCB</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon</intervention_name>
    <description>After predilation, using drug-coated balloon catheter to cover the whole treated segment</description>
    <arm_group_label>DCB Treatment Group</arm_group_label>
    <other_name>Zylox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age during 18-85 years old&#xD;
&#xD;
          -  Arteriovenous fistula is matured and has undergone one or more hemodialysis sessions&#xD;
&#xD;
          -  Venous stenosis of the AV fistula&#xD;
&#xD;
          -  target lesion has stenosis ≥50% evidenced by angiography. and have at least one&#xD;
             symptom of these：1,the venous pressure increased significantly during dialysis.&#xD;
             2,abnormal physical examination. 3,Decrease in blood flow&#xD;
&#xD;
          -  the length of target lesion ≤100mm&#xD;
&#xD;
          -  Patient able to give informed consent&#xD;
&#xD;
          -  residual stenosis ≤30% after predilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are breastfeeding, pregnant or are intending to become pregnant&#xD;
&#xD;
          -  AVF located at lower limbs&#xD;
&#xD;
          -  Two or more than two stenosis at the target vessel.&#xD;
&#xD;
          -  Obstruction of central venous return&#xD;
&#xD;
          -  ISR&#xD;
&#xD;
          -  AVF with acute thrombosis requiring lysis or thrombectomy in 30 days&#xD;
&#xD;
          -  Vascular access has surgery in 30 days or intending to undergo a surgery&#xD;
&#xD;
          -  Known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium,&#xD;
             etc.&#xD;
&#xD;
          -  Patients undergoing immunotherapy or suspected / confirmed vasculitis&#xD;
&#xD;
          -  Patients with history of blood coagulation dysfunction and history of thrombocytopenic&#xD;
             purpura&#xD;
&#xD;
          -  Vascular access infection or systemic active infection&#xD;
&#xD;
          -  Patients's life expectancy is less than 12 months&#xD;
&#xD;
          -  Renal transplantation has been planned or converted to peritoneal dialysis&#xD;
&#xD;
          -  Other medical conditions that lead to researchers who believe that patients may not be&#xD;
             able to follow the trial program&#xD;
&#xD;
          -  Involved in other drugs, biology, medical device research, or has been involved in&#xD;
             other similar products clinical Test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lan Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Liang, Bachelor</last_name>
    <phone>13819565660</phone>
    <email>jie.liang@zyloxmedical.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DCB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

